Tosagestin

Tosagestin
Clinical data
Other namesORG-30659; Exogestin; Letogestin;[1] 11-Methylene-δ15-norethisterone; 17α-Ethynyl-11-methylene-19-nor-δ15-testosterone
Routes of
administration		By mouth
Identifiers
IUPAC name
  • (1S,2R,10R,11S,14R,15S)-14-ethynyl-14-hydroxy-15-methyl-17-methylidenetetracyclo[8.7.0.02,7.011,15]heptadeca-6,12-dien-5-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H24O2
Molar mass308.421 g·mol−1
3D model (JSmol)
SMILES
  • CC12CC(=C)C3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34
InChI
  • InChI=1S/C21H24O2/c1-4-21(23)10-9-18-17-7-5-14-11-15(22)6-8-16(14)19(17)13(2)12-20(18,21)3/h1,9-11,16-19,23H,2,5-8,12H2,3H3/t16-,17-,18-,19+,20-,21-/m0/s1
  • Key:YJSTYQGZKJHXLN-OLGWUGKESA-N

Tosagestin (INN, USAN) (developmental code name ORG-30659), also known as 11-methylene-δ15-norethisterone or 17α-ethynyl-11-methylene-19-nor-δ15-testosterone, is a progestin of the 19-nortestosterone group which was under development by Organon in the United States and Europe as a hormonal contraceptive (in combination with ethinylestradiol) and for the treatment of menopausal symptoms but was never marketed.[2][3][4][5][6]

See also

References

  1. ↑ Martin Negwer; Hans-Georg Scharnow (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 2104. ISBN 978-3-527-30247-5.
  2. ↑ World Health Organization (2013), The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (PDF), p. 95, archived from the original (PDF) on August 8, 2016
  3. ↑ AdisInsight, Tosagestin, Springer, retrieved 12 July 2016
  4. ↑ Verhoeven CH, Krebbers SF, Wagenaars GN, Booy CJ, Groothuis GM, Olinga P, Vos RM (1998). "In vitro and in vivo metabolism of the progestagen Org 30659 in several species". Drug Metab. Dispos. 26 (11): 1102–12. PMID 9806953.
  5. ↑ de Visser, S.J.; Uchida, N.; van Vliet-Daskalopoulou, E.; Fukazawa, I.; van Doorn, M.B.A.; van den Heuvel, M.W.; Machielsen, C.S.M.; Uchida, E.; Cohen, A.F. (2003). "Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE)". Contraception. 68 (3): 195–202. doi:10.1016/S0010-7824(03)00140-9. ISSN 0010-7824. PMID 14561540.
  6. ↑ Obruca, Andreas; Korver, Tjeerd; Huber, Johannes; Killick, Stephen R; Landgren, Britt-Marie; Struijs, Martin J (2001). "Ovarian function during and after treatment with the new progestagen Org 30659". Fertility and Sterility. 76 (1): 108–115. doi:10.1016/S0015-0282(01)01824-6. ISSN 0015-0282. PMID 11438328.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.